Nasdaq grants Avenue Therapeutics continued listing exception; AnnJi seeks to terminate AJ201 license

AVENUE THERAPEUTICS, INC.

Nasdaq Panel granted continued listing subject to: public disclosure by Mar 14, fundraising update by Mar 14, AJ201 trial results by Apr 15.
AnnJi sent termination notice alleging material breaches of AJ201 license; Avenue believes claims are meritless and will contest.
Avenue filed emergency arbitration to block AnnJi from unblinding clinical data in a way that would exhaust irreplaceable samples.
Company must still regain compliance with stockholders' equity requirement; no assurance of success.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001437749-25-006685
form_type: 8-K
ticker: ATXI
cik: 0001644963
company_name: AVENUE THERAPEUTICS, INC.
filed_at: 2025-03-07T23:59:59+00:00
discovered_at: 2026-05-14T18:03:04.288906+00:00
generated_at: 2026-05-25T03:44:33.315138+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: negative
materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001437749-25-006685
json_url: https://secwatch.observer/filing/0001437749-25-006685.json
markdown_url: https://secwatch.observer/filing/0001437749-25-006685.md
text_url: https://secwatch.observer/filing/0001437749-25-006685.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1644963/000143774925006685/0001437749-25-006685-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1644963/000143774925006685/atxi20250307_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001437749-25-006685

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.